Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 9/2019

04.09.2019 | Thymome | zertifizierte fortbildung

Inhomogene Tumorentität

Bei Thymustumoren steht die chirurgische Therapie noch im Vordergrund

verfasst von: Dr. Heidrun Grosch

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Thymustumoren sind eine inhomogene Gruppe von Neoplasien unterschiedlicher Malignitätsgrade und prognostischer Perspektive. Die Operation ist der Goldstandard der Therapie. Im fortgeschrittenen Stadium ist eine interdisziplinäre Behandlung mit Beteiligung der Bereiche Chirurgie, Strahlentherapie und Onkologie nötig, angesichts der Seltenheit dieser Tumoren in Spezialzentren. Mit Vorsicht kann auch eine Immuntherapie indiziert sein.
Literatur
2.
Zurück zum Zitat Marx A et al. The Autoimmune Regulator AIRE in Thymoma Biology Autoimmunity and Beyond. J Thorac Oncol. 2010;5(10 Suppl 4):S266–72CrossRefPubMed Marx A et al. The Autoimmune Regulator AIRE in Thymoma Biology Autoimmunity and Beyond. J Thorac Oncol. 2010;5(10 Suppl 4):S266–72CrossRefPubMed
3.
Zurück zum Zitat Marx A et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol. 2015;10(10):1383–95CrossRefPubMedPubMedCentral Marx A et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol. 2015;10(10):1383–95CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Detterbeck FC et al. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Propsal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol. 2014;9(9 Suppl 2):S65–72CrossRefPubMed Detterbeck FC et al. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Propsal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol. 2014;9(9 Suppl 2):S65–72CrossRefPubMed
5.
Zurück zum Zitat Koga K et.al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44(5):359–67CrossRefPubMed Koga K et.al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44(5):359–67CrossRefPubMed
6.
Zurück zum Zitat Refaeley Y et al. Resection and perfusion thermochemotherapy: A new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg. 2001;72(2):366–70CrossRef Refaeley Y et al. Resection and perfusion thermochemotherapy: A new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg. 2001;72(2):366–70CrossRef
7.
Zurück zum Zitat Ried M et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumors: perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43(4):801–7CrossRefPubMed Ried M et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumors: perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43(4):801–7CrossRefPubMed
8.
Zurück zum Zitat Girard N et al. Thymic epithelial tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v40–55CrossRefPubMed Girard N et al. Thymic epithelial tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v40–55CrossRefPubMed
9.
Zurück zum Zitat Merveilleux du Vignaux C et al. Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13(11):1762–70CrossRefPubMed Merveilleux du Vignaux C et al. Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13(11):1762–70CrossRefPubMed
10.
Zurück zum Zitat Thomas A et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16(2):177–86CrossRefPubMedPubMedCentral Thomas A et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16(2):177–86CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Zucali PA et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 2018;36(4):342–9CrossRefPubMed Zucali PA et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 2018;36(4):342–9CrossRefPubMed
12.
Zurück zum Zitat Loehrer PJ et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma. J Clin Oncol. 2004;22(2):293–9CrossRefPubMed Loehrer PJ et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma. J Clin Oncol. 2004;22(2):293–9CrossRefPubMed
13.
Zurück zum Zitat Kirzinger L et al. Octreotide LAR and prednisone as neoadjuvant treatment in patients with primary or locally recurrent unresectable thymic tumors: A phase II study. PLoS One. 2016;11(12):e0168215CrossRefPubMedPubMedCentral Kirzinger L et al. Octreotide LAR and prednisone as neoadjuvant treatment in patients with primary or locally recurrent unresectable thymic tumors: A phase II study. PLoS One. 2016;11(12):e0168215CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Cho J et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol. 2019;37(24):2162–70.CrossRefPubMed Cho J et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol. 2019;37(24):2162–70.CrossRefPubMed
15.
Zurück zum Zitat Giaccone G et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19(3):347–55CrossRefPubMed Giaccone G et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19(3):347–55CrossRefPubMed
16.
Zurück zum Zitat Rieker RJ et al. An Institutional Study on Thymomas and Thymic Carcinomas: Experience in 77 Patients. Thorac Cardiovasc Surg. 2008;56(3):143–7CrossRefPubMed Rieker RJ et al. An Institutional Study on Thymomas and Thymic Carcinomas: Experience in 77 Patients. Thorac Cardiovasc Surg. 2008;56(3):143–7CrossRefPubMed
17.
Metadaten
Titel
Inhomogene Tumorentität
Bei Thymustumoren steht die chirurgische Therapie noch im Vordergrund
verfasst von
Dr. Heidrun Grosch
Publikationsdatum
04.09.2019
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 9/2019
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-019-6367-6

Weitere Artikel der Ausgabe 9/2019

InFo Hämatologie + Onkologie 9/2019 Zur Ausgabe